On Jan 22, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division. Ulrik B. Nielsen, Ph.D. will be stepping down as the head of the Discovery division and has been elected to serve on Merrimack’s Board of Directors. Anthony J. Sinskey, Sc.D. will also be resigning from the Board of Directors and will continue as a scientific advisor. All of these transitions will occur on January 30, 2015. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) belongs to Healthcare sector. Its weekly performance is -10.67%. On last trading day company shares ended up $9.71. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is -4.05%.

American Airlines Group Inc. (NASDAQ:AAL) has canceled all late afternoon and evening flights scheduled for Monday from the New York area, Philadelphia and Boston as a major winter storm bears down on the northeast, spokeswoman Andrea Huguely said. American Airlines Group Inc. (NASDAQ:AAL) shares decreased -0.43% in last trading session and ended the day at $55.45. AAL Gross Margin is 27.00% and its return on assets is 0.60%. American Airlines Group Inc. (NASDAQ:AAL) quarterly performance is 44.48%.

General Communication (NASDAQ:GNCMA) COO Gregory F. Chapados sold 25,000 shares of General Communication stock on the open market in a transaction dated Thursday, January 15th. The shares were sold at an average price of $14.75, for a total transaction of $368,750.00. Following the completion of the transaction, the chief operating officer now directly owns 500,275 shares of the company’s stock, valued at approximately $7,379,056.25. On 26 January, General Communication Inc. (NASDAQ:GNCMA) shares decreased -0.70% and was closed at $15.58. GNCMA EPS growth in last 5 year was 50.60%. General Communication Inc. (NASDAQ:GNCMA) year to date (YTD) performance is 13.31%.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that the U.S. Food and Drug Administration or FDA has granted Fast Track designation for BCX4161, a novel, orally administered, selective inhibitor of plasma kallikrein in advanced clinical development for the treatment of hereditary angioedema. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) belongs to Healthcare sector. Its weekly performance is 0.71%. On last trading day company shares ended up $11.33. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) distance from 50-day simple moving average (SMA50) is 3.13%.

On Jan. 22, OceanFirst Financial Corp. (NASDAQ:OCFC) announced that diluted earnings per share increased to $0.30 for the quarter ended December 31, 2014, as compared to $0.11 for the corresponding prior year period. For the year ended December 31, 2014, diluted earnings per share increased to $1.19, as compared to $0.95 for the prior year. OceanFirst Financial Corp. (NASDAQ:OCFC) shares decreased -0.97% in last trading session and ended the day at $16.39. OCFC return on assets is 1.10%. OceanFirst Financial Corp. (NASDAQ:OCFC) quarterly performance is 3.21%.